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Abstract This study investigated the effectof lowdose of budesonide100 mg b.d from a newmulti-dose drypowder
inhaler (AirmaxTM) and froma conventionalinhaler (Turbuhalers) onbronchialhyper-responsiveness, lung function and
asthma symptomsinmild stable asthmatics.Twenty-fivepatientswereenrolledinto adouble-blinddouble-dummycross-
over study withtwo 4-week treatment periods separated by a 4-weekwashout.Patients had amean forced expiratory
volumein1s (FEV1) of 91713% predicted, hadpreviouslyreceivedinhaled short-acting b2-agonists onlyandhada PC20 to
adenosine 5
0
monophosphate (AMP)o40mg/ml. PC20 AMP was assessed at baseline, and at the start and end of each
treatment period. Patients recorded peak expiratory flow and symptoms throughout the study.There was a mean in-
crease in PC20AMP from start to end of 3.49 doubling dilutions (DD) in the Airmax
TMgroup and 2.90 DDin theTurbu-
halers group.The difference was 0.60 DD(95% CIF0.47,1.69) favouring AirmaxTM and the upper limit exceeded the
equivalencelimitof71DD.Therewere similarimprovementsin FEV1, daily PEFand symptomsinbothgroups.Themajor-
ityof patientspreferredtreatmentwith AirmaxTM toTurbuhalers (64 vs.23%).Bothtreatmentswere equallywell toler-
ated.In conclusion,100 mg budesonide bid during 4 weeks from AirmaxTM effectively attenuates the response to AMP in
mild asthmatics.Overall AirmaxTMoffers equalclinicalbenefittoTurbuhalersandispreferredbypatients.r2002 Published
by Elsevier Science Ltd
doi:10.1053/rmed.2002.1290, available online at http://www.idealibrary.comon
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Bronchial hyper-responsiveness (BHR) is a characteristic
feature of bronchial asthma. Histamine and methacho-
line are generally used to assess the severity of BH and
both have direct e¡ects on smooth muscle cell contrac-
tion (1). Adenosine 50 -monophosphate (AMP) is a stimu-
lus which acts by causing the release of mediators from
mast cells, thereby indirectly causing smoothmuscle cell
contraction (2). Previous studies have shown that the
provocative concentration (PC20 AMP) producing a 20%Received 28 December 2001, accepted in revised form 2 January 2002
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Medical A¡airs Europe,Yamanouchi Europe BV, Elisabethhof19,NL-
2350 ACLeiderdorp,The Netherlands.Fax: +31715455739fall in forced expiratory volume in1s (FEV1) is more sen-
sitive to treatment with corticosteroids than PC20
methacholine (3^5). A recent study also showed that
PC20 AMPwasmore closely related to airway in£amma-
tion than PC20 methacholine in asthmatic patients (6)
making AMP the stimulus of choice for the investigation
of the clinical e¡ects of steroid treatments from novel
inhalation devices (3^6).
TheAirmaxTMdrypowder inhaler hasbeendeveloped
to ensure easy, accurate, virtually orientation free and
consistent dosing of up to 200 doses of drug powder
from a single inhaler.The inhaler was developedbyYama-
nouchi Europe in conjunction with Ivax Pharmaceuticals
Ltd and uses proprietary technology known as the X-
ACTt system. The inhaler has an integral mouthpiece
and is easy to use by simply opening the mouthpiece,
FIG 1. Study schedule.
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vantage of the AirmaxTM inhaler is that it achieves a high
degree of dispersion of drug particles with a high respir-
able fraction that canbe achievedeven at low inspiratory
£ow rates (i.e. 25^30 l/min) (7,8).
The objective of this study was to evaluate the e¡ect
of a low dose of budesonide (100mg twice daily) adminis-
tered via AirmaxTM and via Turbuhalers on BHR (PC20
AMP), lung function, asthma symptoms and the need
for rescuemedication inmild asthmatic patients.
METHODS
Patients
Adult asthmatic patients aged 16 years were selected
from the outpatientdepartments of twohospital centres
in theU.K.Written informed consentwas obtained from
each subject before his or her participation in the study.
Patients had FEV1 of 60% of that predicted for age,
height and gender and had only received inhaled short-
acting b-agonists in the 4 weeks prior to enrolment. Pa-
tients were not eligible if they had a PC20 AMP440mg/
ml at screening, were receiving or had received within
the previous month, therapy for an upper respiratory
tract infection, had received emergency treatment or
been hospitalised for an asthma exacerbationwithin the
previousmonth, or had received one course of oral cor-
ticosteroid treatment within the past 3 months or more
than three such courses within the previous 12 months.
Patients were also excluded if they had received
methyl xanthines, sodium cromoglycate or nedocromil
sodium, vasoconstricting or vasodilating agents, or
intranasal corticosteroids within the previous
month. Patients were additionally excluded if at the
start of the treatment phase of the study, 1 week after
screening, PC20 AMP was more than 71 doubling dilu-
tion (DD) di¡erent from the baseline value recorded at
visit1.
Study design andprocedures
This randomised double-blind double-dummy crossover
study was approved by Local Research Ethics Commit-
tee at both centres. Following a1-week run-in period to
establish baseline values, patients were randomly as-
signed to receive budesonide100mg twice daily for a per-
iod of 4 weeks from either AirmaxTM orTurbuhalers. At
the endof the ¢rst 4-week treatmentperiod therewas a
4-week washout during which only short-acting b-ago-
nists were allowed, following which patients crossed
over to the alternative treatment. Any patients who
had taken any of the medications excluded at screening
were to be withdrawn. Patients received placebos
matching the alternative treatment in order to maintain
the study blind. Patients attended the clinic on a total ofseven occasions: at the start andendof therun-inperiod
and each treatment period, and after 2 weeks of each
treatment period (Fig. 1). Bronchial responsiveness to
AMP challenge was assessed at the screening visit and
at the start and end of each treatment period.The chal-
lenge procedure with AMP was on each occasion pre-
ceded by forced inhalation of ¢ve breaths of normal
saline. If a fall in FEV1of greater than10% occurred after
saline, the procedure was to be aborted as the subject
was deemed to be too reactive. AMP was administered
via a Medic-Aid nebuliser in doubling concentrations
from 0.195mg/ml up to a maximum of 800mg/ml every
5min.The air supply to the nebuliser was set at 8 l/min
to produce a massmedian particle diametero5mm at a
rate of 0.25^0.50ml/min. FEV1 was measured in dupli-
cate both1and 3min after each inhalation and the lower
of the two highest values at each time point was used in
the analysis.Theprocedurewas terminatedwhen a fall in
FEV1of20%was observed. Peak expiratory £ow (PEF),
measured with a Mini-Wrightt peak £ow meter, and
FEV1, measured using a calibrated spirometer with the
subject in the sittingposition,were also recorded at each
clinic visit. Patients were provided with a mini-Wright
peak £ow meter and recorded the best of three mea-
surements of morning and evening PEF on a daily diary
card throughout the study. Daily recordings were made
also of asthma symptoms and the use of rescue medica-
tion. Day-time symptoms were scored as 0=none;
1=wheezing or shortness of breath on strenuous exer-
cise/hurrying, otherwise asthma not unduly trouble-
some; 2=wheezing or shortness of breath most of the
day, normal activities di⁄cult; 3=unable to carry out
normal activities because of shortness of breath. Night-
time symptoms were scored as 0=none; 1=symptoms
caused waking once, or early waking; 2=woken 2 or 3
timesbycough/wheeze/breathlessness/asthma; 3=awake
most of the night with cough/wheeze/breathlessness/
asthma. Patients were not allowed to take any asthma
medication other than study medication and short-act-
ing b2-agonists throughout the study. Anti-histamines
and topical nasal anticholinergics were permitted
544 RESPIRATORYMEDICINEprovided they were withheld for at least 48h prior to
each study visit. Patients were also asked if they had a
preference for either inhaler or whether they found
them equally acceptable or unacceptable. Subjective as-
sessments of ease of use of the inhalersweremade at the
end of each treatment period on a 0 (very di⁄cult) to10
(very easy) rating scale.
Data analyses
Theprimary e⁄cacy parameter was the PC20 FEV1to in-
haledAMP (expressed asDD) following 4weeks of treat-
ment.The di¡erencebetween treatmentswas calculated
by comparing the di¡erence (postpre) log PC20 after
the AirmaxTM and Turbuhalers treatments in each indi-
vidual subject, expressed in terms of doseDD,mean and
95% con¢dence intervals (CI) using the formula: {(post-
pre)logPC20MDPI-(postpre)logPC20 TFI}/ log10 2.
Equivalence between both treatments was to be de-
clared if the 95% CI for the di¡erence between the PC20
for the two treatments was within71DD.Basing calcu-
lations on an estimated variance of 1.7 DD, 24 evaluable
patients were required to detect equivalence with a
power of 90%. Although power analysis was based on
the primary endpoint, clinical equivalence was also ex-
amined by investigating whether the 95% CI of the ratio
of themean FEV1and PEF response at endpointwas con-
tained within 90^111%. All analyses were based on the
per protocol population. (PPP)
RESULTS
Patients
A total of 55 patients were screened for the study, of
whom 25 were randomised comprising the intent to
treat population (ITT) and 22 comprised the PPP. TheTABLE 1. Patients demographics and baseline characteristics by
Treatmentorder AirmaxTM/Turbuhalers
Parameter
Numberof patients 12
Males: females (%) 6:6(50:50)
Age (years)7SD 3576
Height (cm)7SD 170.378.1
Weight (kg)7SD 74.0713.1
FEV1(L)7SD 3.1170.57
FEV1(%predicted)7SD 89.8713.8
PEF (l/min)7SD 509.2773.4
PC20FEV1AMP
mg/ml7SD 12.75710.56
Doublingdilutions 3.2071.26majority of the non-randomised patients failed to meet
all inclusion and exclusion criteria. Two of the patients
were excluded from the PPP.One withdrew voluntarily
and onewas randomised in error, having failed the varia-
bility check at visit 2.The treatment order groups were
generally well matched by age, weight, baseline lung
function and bronchial hyper-responsiveness (Table1). A
higher number of females were recruited in the Air-
maxTM/Turbuhalers treatment order group.
AMPchallenge data
Mean PC20 AMP increased by160.4 from19.5mg/ml pre-
treatment to 180.7mg/ml post-treatment for patients
treated with AirmaxTM and by 101.7mcg/ml from 12.1 to
112.9mg/ml for patients treated with Turbuhalers. One
patient failed to achieve a fall of 20% in FEV1at the high-
estconcentration on one occasion andwas assigneda va-
lue of1000mg/ml for PC20 FEV1. Individual response data
are shown in Fig. 2.Expressed as DD, the increases were
3.49 DD for AirmaxTM and 2.90 DD forTurbuhalers, re-
spectively, with a treatment di¡erence of 0.60 DD (95%
CIF0.47,1.69)(Table 2). After excluding the patient who
did not achieve a PC20 AMP, the increases were 3.21DD
for AirmaxTM and 2.84 DD forTurbuhalers with a treat-
ment di¡erence of 0.37 DD (95% CIF0.56,1.29).
Lung function anddiary cardmeasurements
Mean FEV1increasedby 0.17 from3.1670.58 l (92.7% pre-
dicated) to 3.3370.75 l (97.1% predicted) in theAirmaxTM
group as compared to an increase of 0.25 l from
3.0770.70 (89.6% predicted) to 3.3270.72 l (96.8%) in
theTurbuhalers group (Table 3).These ¢ndingswere also
re£ected in increases in average morning and evening
PEF, and improvements in asthma symptoms and rescue
medication use (Table 3). Statistical analysis showed thattreatmentorder (PP population)
Turbuhalers/AirmaxTM Overall
10 22
2:8(20:80) 8:14(36:64)
32710 3478
169.277.8 169.877.8
76.6718.5 75.3715.7
3.1670.55 3.1370.55
95.0711.3 92.1712.7
476.0774.0 494.1773.9
13.6678.71 13.6179.55
3.4371.16 3.3071.19
FIG 2. Individual changes in PC20 (mg/ml) pre- and post-treatment following 4-week treatment with either Airmax
TM orTurbuha-
lers (excluding one patientwith1000 mg/ml).
TABLE 2. Mean and changes in PC20FEV1 (doubling dilutions) following 4 weeks treatment with 100mcg budesonide bid by
either AirmaxTMorTurbuhalers (PP population)
AirmaxTM
(N=22)
Turbuhalers
(N=22)
LSMaDi¡erence
(95%CI)
Baseline(SD) 3.2471.74 3.0171.46 F
Endpoint(SD) 6.7471.81 5.9271.91 F
Change (endpoint-baseline) 3.4972.04 2.9071.74 0.60(0.47,1.69)
aLSM: least squaremeans.
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equivalence range 90^111% and that therewereno statis-
tically signi¢cant di¡erences between treatments with
respect to other secondary clinical parameters.
Inhaler preference and ease of use
Fourteen (64%) out of 22 patients preferred the Air-
maxTM inhaler, 5 patients (23%) preferred Turbuhalers
and 3 patients (14%) had no preference. In terms of ease
of use on a scale from 0 to10, AirmaxTM was rated at 9.5
and Turbuhalers at 8.0.
Safety
Of the 25 randomised patients 21(84%) reported ad-
verse events (mostly headache, pharyngitis, cough), but
in only two instances (coughing and pharyngitis) were
these considered to be possibly related to the test treat-
ment. Table 4 shows the numbers of patients reporting
treatment emergent events when these occurred in
more than 5% of patients overall (i.e. occurring in more
than one subject). No patients withdrew on account ofadverse events and no serious events were reported.
There were no clinically signi¢cant di¡erences between
the two treatments in terms of adverse events.
DISCUSSION
Treatment with a low dose of budesonide (100mg bid)
from a new inhaler AirmaxTM over 4 weeks resulted in a
signi¢cant attenuation in airway responsiveness to AMP
and improvements in lung function and symptoms inmild
asthma patients. Overall treatment response with Air-
maxTM was similar to that of Turbuhalers. Both treat-
ments were well tolerated with a similar incidence and
pattern of adverse events.Most of thesewere headache,
pharyngitis and coughing and the majority were not re-
lated to treatment.
The magnitude of the treatment e¡ect was compar-
able to that observed in earlier studies comparing ster-
oid doses ranging from 50 to 800mg bid to placebo in
mild-to-moderate asthmatic patients (9^11).The present
study enrolled mild asthmatics (with a mean predicted
FEV1of 92%) and used a low dose of inhaled budesonide
(100mg bid). As PC20 AMP has been shown to be closely
TABLE 3. Meanchanges in lung function and asthma symptoms frombaseline to endpoint (PP population)
Parameter AirmaxTM
(N=20)
Turbuhalers
(N=20)
Ratio MDPI:TH(95%CI)
Clinic FEV1(l)
Baseline 3.16 3.07
Endpoint 3.33 3.32 100.4(97.9,102.9)
Change 0.17 0.25
Clinic FEV1(% predicated)
Baseline 92.7 89.6 F
Endpoint 97.1 96.8
Change 4.4 7.2
Morning PEF(l/min)
Baseline 444.0 438.9
Endpoint 460.7 464.4 99.2(97.5,100.8)
Change 16.7 25.5
Evening PEF(l/min)
Baseline 451.9 445.4
Endpoint 464.9 465.4 99.8(98.0,101.6)
Change 13.0 20.0
Pu¡s ofrescuemedication(per week)
Baseline 1.4 1.2
Endpoint 0.6 0.4 P=NS
Change 0.8 0.8
Asthma symptoms day-time(0^4)
Baseline 0.23 0.35
Endpoint 0.05 0.10 P=NS
Change 0.18 0.25
Asthma symptoms night-time (0^4)
Baseline 0.20 0.15
Endpoint 0.08 0.05 P=NS
Change 0.12 0.10
TABLE 4. Adverse events occurring in45% of patients overall
Adverse event Numberof patients
AirmaxTM
(N=25)
Turbuhalers
(N=25)
Overall
(N=25)
Headache 4 (17%) 3 (13%) 7 (28%)
Pharyngitis 3 (13%) 3 (13%) 6 (24%)
Coughing 2 (8%) 1 (4%) 3 (12%)
Rhinitis 3 (13%) 0 3 (13%)
Allergic reaction 2 (8%) 0 2 (8%)
Migraine 2 (8%) 0 2 (8%)
Ulcerative stomatitis 0 2 (8%) 2 (8%)
Upper respiratory tract infection 1 (4%) 1 (4%) 2 (8%)
Vomiting 2 (8%) 0 2 (8%)
546 RESPIRATORYMEDICINEassociated with airway in£ammation (5), this con¢rms
that there is considerable room for improvement in re-
ducing airway in£ammation in these mild asthmatic pa-
tients with an almost normal lung function.The present
study also con¢rms the sensitivity of the AMP bronchial
challenge as amarker for treatmentevenwith a lowdoseof inhaled corticosteroids.The overall attenuation in re-
sponse to AMP of approximately three DD was also
accompanied by an increase in lung function and a de-
crease in asthma symptoms and use of relief medication.
The small improvements in FEV1 and PEF were consis-
tently numerically greater, though not signi¢cantly, for
BUDESONIDEFROMAIRMAX TMINBRONCHIALHYPER-RESPONSIVENESS 547Turbuhalers than for AirmaxTM. Despite the fact that
this study was underpowered to compare lung function
endpoints, clinical equivalencebetweenboth treatments
was shown.
The attenuation of response to AMP was larger after
treatment with AirmaxTM than treatment withTurbuha-
lers and equivalence was not shown by a small margin.
This could either be a chance ¢nding or re£ecting a true
e¡ect. As the study recruited only 22 evaluable patients
where 24 patients were required for AMP equivalence
testing a chance ¢nding cannot be excluded as a conse-
quence of a reduced power. A true e¡ect could be
caused by di¡erences in drug delivery characteristics be-
tween the two inhalers.Van Den Berge et al. (6) showed
earlier that an AMP challenge is a more sensitivemarker
for detecting small dose di¡erences of inhaled steroids
than FEV1or PEF. Although both inhalers in the present
study deliver the same nominal dose of drug, it is well
documented that the delivery characteristics ofTurbuha-
lers lack consistency from dose to dose and that the re-
spirable dose is reduced signi¢cantly at low inspiratory
£ow rates (12,13). AirmaxTM, in contrast, has demon-
stratedhigh-doseuniformityin vitro, and a highrespirable
fraction largely independent on inspiratory £ow (1,2). In a
human gamma scintigraphy study, AirmaxTM delivered a
similar amount of drug to the lungs at inspiratory £ows
between 30 and 60 l/min, whereas the performance of
Turbuhalers dropped to 50% at the inspiratory £ow of
30 l/min (8). Although most patients can easily achieve
respiratory £ows of at least 60 l/min (14), incorrect inha-
ler handling and inhalation technique could lead to re-
duced delivery of drug from inhalers. In the present
study, patient clearly preferred AirmaxTM compared to
Turbuhalers andpreferencemayhave in£uencedcompli-
ance with treatment. It could be speculated that a com-
bination of the above factors could have led to better or
more consistentdeposition of budesonide in the lung and
consequently to our failure to showequivalence forAMP
challenge by a smallmargin.However, the overall clinical
response including lung function and asthma symptoms
was very similar for both inhalers.
In conclusion, treatment with a low dose of budeso-
nide (100mg bid) from AirmaxTM during 4 weeks e¡ec-
tively reduced BHR to AMP in steroid-naive mild
asthmatic patients with almost normal lung function.
Overall, the e⁄cacy and safety of the treatment were
equal to that provided by the same dose fromTurbuha-
lers. AirmaxTMwaspreferredby themajorityofpatients
in this study.Acknowledgements
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